10 June 2026 | 3:32AM EDT Equity Research Royalty Pharma Plc (RPRX): 47th Annual Global Healthcare Conference — Key Takeaways Presenters: Christopher Hite, Chairman, Partnering & Investments Bottom Line: In an upbeat discussion, RPRX management provided an overview of the business and current dynamics, noting 1) there continues to be significant growth in synthetic royalties, which have grown from representing ~3% of biopharma funding (through 2024) to ~5% (through 2025), representing approximately $15 bill ...